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1.Introduction 
1.1 MVs as mediator of cellular communication 	  
Cell-to-cell communication is required to guarantee proper coordination among different cell types. 
Communication between cells is mediated mainly by extracellular molecules such as growth factor, 
cytokines, chemokines, hormones. Some of these molecules operate over long distances, signaling 
to cells far away; others signal only to immediate neighbors (Alberts, 2002). Cell can also 
communicate and exchange information through cell-to-cell contact, mediated by specialized 
adhesion molecules or through the release of membrane vesicle (Camussi et al, 2010). Cell–cell 
communication mediated by membrane vesicles emerged very early during evolution and served as 
a template for the further development of intercellular interaction mechanisms involving soluble 
bioactive mediators and fine-tuned ligand–receptor interactions (Ratajczak et al, 2011). Two classes 
of membrane vesicles have been described in literature: exosomes and shed vesicles (MVs). 
 
1.1.1 Exosomes 	  
Exosomes are a population of small membrane vesicles (50-90 nm) released by an endocytic 
pathway (Fig. 1). Exsosomes generation take place inside the lumen of multivesicular bodies 
(MVBs) by budding, fission ad segregation of their membrane. MVBs are ubiquitous membrane-
bound organelle that works as intermediates in endolysosomal transport. Based on their biochemical 
properties, intracellular MVBs can either traffic to lysosomes, where they are subjected to 
Fig.	  1:Generation	  of	  exosomes	  and	  shed	  vesicles.	  (Cocucci	  et	  al,	  2009)  
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proteosomal degradation (degradative MVBs), or to the plasma membrane, where release exosomes 
in the extracellular space (exocytic MVBs) upon fusion with the plasma membrane (Mathivanan et 
al, 2010). Sorting of vesicles inside MVBs is a regulated pathway, generally involving the ESCRT 
(endosomal sorting complex required for transport) machinery, which regulates membrane scission. 
Recent studies indicate that fission of exosome membrane is catalyzed by components of the 
ESCRT-III complex, called charged multivesicular body proteins (CHMPs); (Hanson et al, 2009; 
Wollert & Hurley, 2010; Wollert et al, 2009) and by the AAA-ATPase vacuolar protein sorting-
associated 4, VPS4 (Babst, 2005). Several other factors have been identified that promote exosome 
biogenesis, including the sphingolipid ceramide produced by neutral sphingomyelinase (N-SMase)	  
(Kosaka et al, 2010; Trajkovic et al, 2008). The fusion of MVBs and consequently the release of 
exosomes in the extracellular space can occur either in a constitutive way or in response to specific 
stimuli. 
Exosomes are enriched in several proteins and lipids of the MVBs membrane, while depleted of 
many other. Indeed for these constituents, exosome biogenesis serves as a mechanism of regulated 
assembly of MVB components. As consequence of their endosomal origin exosomes contain 
numerous protein involved in membrane transport and fusion (i.e. annexin, flotillin, Rab GTPases), 
in MVBs biogenesis (Alix), besides integrins and tetraspanins (CD63, CD9, CD81, CD82). They 
are also characterized by the presence of high levels of cholesterol, sphingolipids, ceramide and 
glycerophospolipids in their membrane	  (Simons & Raposo, 2009).  
 
1.1.2 Microvescicles  	  
Microvesicles (MVs), also referred to as shed vesicles or ectosomes (Sadallah et al, 2011), are a 
population of quite large membrane vesicles that are more heterogeneous in size (100nm-1µm) and 
shape as compared to exosomes. They bud directly from the plasma membrane and are released into 
the extracellular environment upon cell activation (Fig. 1). Shedding of MVs typically involves a 
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budding process, in which surface blebs selectively accumulates cellular constituents that are then 
packaged into MVs. MVs contain a variety of cell surface receptors, intracellular signalling proteins 
and genetic materials derived from the cell of origin. In terms of composition, MVs shed from 
distinct cells are molecularly different from each other, reflecting the differential expression of 
proteins of various donor cells. Composition and biological activity of MVs also vary depending on 
the state (e.g. resting, stimulated) of donor cells and depending on the agent employed for 
stimulation (Bernimoulin et al, 2008). However, shed vesicles are generally characterized by the 
presence of high levels of phosphatidylserine (PS) on their surface.  
 
1.1.3 Shedding of MVs induced by P2X7 receptor activation  	  
A specialized type of MV release exists for cells that express the ATP receptor P2X7, which shed 
MVs from the cell surface when exposed to ATP. P2X7 receptor is an ATP-gated ion channel that is 
highly expressed in immune cells, in particular macrophages (Steinberg & Silverstein, 1987) mast 
cells (Cockcroft & Gomperts, 1979) and microglia (Visentin & Levi, 1997), where it controls the 
release of inflammatory cytokines. Activation of P2X7 receptor can induce efficient inflammosome 
assembly and maturation of the inflammatory cytokines IL-18 and IL-1β, which is then followed by 
rapid cytokine secretion (Qu et al, 2007). P2X7 receptor differs from other members of the P2X 
family in its relatively low affinity for ATP and the presence of a long cytoplasmic C-terminus that 
contains several protein–protein interaction motifs. Depending on the concentration of ATP and the 
duration of stimulation, P2X7 receptor can function as an ion channel or a non selective pore, the 
latter generally leading to cytoxicity and apoptotic cell death. Many studies have shown that 
dramatic morphological changes occur in cells endogenously or heterologously expressing P2X7 
receptors during and subsequent to receptor activation (Hogquist et al, 1991). These changes consist 
in rapid formation of cell membrane blebs and are associated to cell death upon sustained P2X7 
receptor activation. Membrane blebbing requires several intra-signalling events, which are activated 
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by occupancy of the receptor such as the action of protein kinases and other effector enzymes 
(Duan & Neary, 2006). In particular, several lines of evidence indicated that blebbing induced by 
P2X7 receptor is dependent on P38 and requires ROCK kinase activation, which causes local 
disassembly of the cytoskeletal elements, associated to the P2X7 receptor C-terminus, (Budagian et 
al, 2003)	  (Morelli et al, 2003; Verhoef et al, 2003). Notably, surface blebbing is preceded by loss of 
plasma membrane asymmetry and exposure of phosphatidylserine (PS) at the outer leaflet of the 
plasma membrane, a process controlled by specific enzymes, named flippase, floppase and lipid 
scramblase, which control PS segregation in the inner leaflet of the plasma membrane. Externalized 
PS is commonly accepted as a marker of a cell undergoing apoptosis. However, a pioneer study by 
Surprenant and colleagues (MacKenzie et al, 2001) reported that P2X7-induced PS externalization 
and bleb formation occur within the first few minutes of receptor activation and may be reversible 
after brief stimulation, thus dissotiating P2X7-induced bleb formation from cell apoptosis in 
monocytes. MacKenzye and colleagues also showed that during blebbing, MVs with externalized 
PS may form and be released into the extracellular space as a result of bleb detachment from the 
cell surface. Notably, during blebbing the pro-inflammatory cytokine IL-1β is packaged into plasma 
membrane blebs and subsequently released into the extracellular space from reactive monocytes as 
MVs. Almost ten year ago these results provided the first evidence that P2X7-induced MV shedding 
acts as a secretory pathway for rapid release of IL-1β and may represent a general mechanism for 
secretion of leaderless secretory proteins from P2X7-expressing myeloid cells. 
Few years ago data obtained in the laboratory demonstrated that a MVs-dependent mechanism IL-
1b release, very similar to that first described in monocytes(MacKenzie et al, 2001), occurs in 
microglial cells (Bianco et al, 2005) and contributed to clarify the mechanism mediating MVs 
shedding in glial cells that express P2X7 receptors.  We found that biogenesis of MVs storing IL-
1β  is controlled by acid sphingomyelinase (A-SMase), the enzyme which hydrolyzes 
sphingomyelin (SM) to the sphingolipid ceramide. Following P2X7 receptor activation and 
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subsequent P38 MAP kinase phosphorilation, A-SMase becomes promptly activated and moves to 
plasma membrane outer leaflet, where generates ceramide, thereby inducing budding of MVs	  (Fig.	  2)	  (Bianco et al, 2009a).  
Formation of blebs is likely caused by redistribution of extracellularly synthetized ceramide within 
the bilayer and by local enrichment of the cone-shape sphingolipid into the inner leaflet of the 
membrane, where it may induce, due to its spontaneous negative curvature, membrane subdomains 
with curvature different from the adjacent planar membrane	  (Subra et al, 2007).  
The key role of A-SMase in MV formation was demonstrated using pharmacological inhibition and 
genetic inactivation of the enzyme.  Both approaches strongly abolished release of MVs and of IL-
1β  from reactive glial cells (Bianco et al, 2009a). These results were consistent with the 
involvement of neutral- (N-) rather than A-SMase and ceramide in the budding of exosomes in 
oligodendrocytes (Trajkovic et al, 2008) and further indicated that the budding of MVs may share 
Fig.	  2:	  Model	  for	  P2X7R-­‐induced	  MVs	  shedding	  in	  glial	  cells	  (Bianco	  et	  al,	  2009a) 
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features with exosome biogenesis. The role of N- and A-SMase in exosome and MV formation, 
respectively, suggest that different members of the SMase family may control the release of distinct 
types of extracellular vesicles from brain cells, independently of the ESCRT complex. 
Other pathways besides shed MVs have been proposed to mediate IL-1β release from myeloid cells, 
including exosomes and exocytosis of secretory lysosomes in monocytes (Qu et al, 2007). 
However, enrichment of IL-1β  in larger MVs, derived from the plasmamembrane, and complete 
blockade of MV shedding and IL-1β release from A-SMase knock-out cells indicated that MV 
shedding represents the major mechanism mediating secretion of the inflammatory cytokine from 
reactive microglial cells.  
MVs shed from glial cells store the pro-inflammatory cytokine IL-1β	   (Bianco et al, 2005), 
angiogenic factors and their respective mRNAs, and matrix metalloproteinases (Al-Nedawi et al, 
2009; Proia et al, 2008; Sbai et al, 2010).  
 
1.1.4  MVs role in communication  	  
In spite of the fact that MVs and exosomes contain numerous proteins, lipids ad RNAs and may be 
released from almost all the cell types both constitutively and upon stimulation; they are 
characterized by different composition depending on the cell origin ad activation state of parental 
cells	  (Distler et al, 2005).  
The content of MVs and exosomes do not reflect the exact composition of the cytoplasm of the 
donor cells. The gene profile array, carry out on MC/9 (a mast-cell line) exosomes displayed 
essential difference in the levels of mRNA transcripts in the exosomes as compared to donor cells.  
Since membrane vesicles are released in the extracellular space they can interact with target cells; 
some evidence suggest that MVs can interact only with specific target cells and not with any cell 
present in the microenviroment (Camussi et al, 2010; Losche et al, 2004). 
Fig. 3: Alternative mechanisms by which MVs may interact with target cells. (Ratajczak, 2011) 
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Different ways by which MVs can stimulate target cells are described shown in Fig.3.  
 
 
MVs can interact with other cells directly by surface expressed proteins like growth factors or by 
bioactive lipids. For example, platelet derived MVs have an important role in coagulation because 
their membrane, that is enrich in externalized phosphatydilserine, favours the assembly of clotting 
factors. Membrane vesicles can also transfer surface receptors between cells; it has been reported 
that MVs derived from tumor can transfer FAS ligand to T cells inducing apoptosis and promoting 
tumor immune escape. Furthermore MVs can deliver proteins to other cells and mediate horizontal 
transfer of genetic material such as mRNA and miRNA. Among other evidence, Deregibus et al. 
(Deregibus et al, 2007) reported that MVs derived from endothelial progenitors cells could transfer 
mRNA to endothelial cells both in vitro and in vivo. Interestingly, Valadi and coworkers  
Fig.	  3:	  Model	  for	  P2X7R-­‐induced	  MVs	  shedding	  in	  glial	  cells	  (Bianco	  et	  al,	  2009a) 
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demonstrated that mRNAs taken up by recipient cells can be translated within the cells 	  (Valadi et 
al, 2007). Indeed they identified three distinct mouse proteins in human mast cells after exposure to 
murine exosomes Notably, these proteins were not present in exosomes secreted from murine mast-
cells	   (Valadi et al, 2007).  The presence of several miRNA has been reported in many 
microvesicles, including those derived from primary human glioblastoma, lung cancer, gastric 
cancer and ovarian cancer (Skog et al, 2008). 
miRNA are small non coding RNA that negatively regulate their mRNA target inducing 
degradation or translational repression. It has been estimated that a single miRNAs could interact 
with more than 200 different mRNA and that minor changes in the expression of a miRNA could 
have big impact on the expression of their target. So the MVs mediated transfer of miRNA can have 
important effect on the phenotype of the recipient cell	  (van der Vos et al, 2011).	   
 
1.1.5   Physological and pathological role of MVs  	  
Despite MVs were originally described as inert debris, MV shedding from the plasma membrane is 
now a recognized mode of intercellular communication and the role of MVs has been reported in 
several physiological and pathological process such as cell proliferation, coagulation, vascular 
function, apoptosis, inflammation and tumor progression. For example platelet derived MVs are 
important mediators of both coagulation and thrombosis. These MVs are released upon collagen 
stimulation and are characterized by the presence of tissue factor (TF) on their membrane. In 
physiological conditions platelet-derived MVs, by acting on macrophages, neutrophils and other 
platelets work as trigger of coagulation. However, p vesicles are also present in the lipid core of 
atherosclerotic plaque where promote thrombotic signals(Cocucci et al, 2009). 
Moreover, vesicles secreted from different cells can influence the immune response; for example 
MVs can present antigen to T cells, or transfer the antigen-MHCII complex to dendritic cells, or 
directly activate natural killer cells and macrophages	  (Thery et al, 2009). During inflammation MVs 
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can act both as anti-inflammatory or pro-inflammatory mediators; neutrophil derived 
microvescicles stimulate the production of anti-inflammatory cytokines and MVs released from 
fibroblasts promote the synthesis of pro-inflammatory cytokines, such as inteleukin-6 (IL-6), the 
monocyte chemotactic protein 1 and metalloproteinase.  
The most well characterized membrane vesicles are those released from blood cells, i.e. platelets, 
leukocytes, erythrocytes, and endothelial cells. However accumulating evidence demonstrate that 
MVs and exosomes can also be released by brain cells and that these particles play an important 
function in the central nervous system (CNS) both in pathologic or healthy conditions. 
For example, exosomes derived from oligodendrocytes control myelination, and those produced 
from Schwann cells support local axonal protein synthesis by delivering ribosomes to injured 
neuron. Moreover exosomes released by neuron may contribute to the spreading of pathogenic 
agents or degenerative proteins like beta-amyloid and alpha-synuclein (Emmanouilidou et al, 2010). 
Also MVs derived from glioma contribute to transfer oncogenic proteins.  
 
1.1.6  Clinical prospective  	  
Besides their important function in cell-to-cell communication and their role in physiological and 
pathological process MVs are emerging as important diagnostic tool and therapeutic target (Cocucci 
et al, 2009). Because of their small size, released MVs can move from the site of discharge and 
enter into biological fluids; MVs has been described in almost all body fluids, including plasma, 
urine, milk, cerebrospinal fluid (CSF)	  (Camussi et al, 2010). 
MVs derived from activated blood platelets, leucocytes and endothelial cells continuously circulate 
in peripheral blood under steady-state conditions, with their number increasing during stress 
situations (e.g. infection, organ tissue damage or neoplasia) (George et al, 1982; Quesenberry et al, 
2010; Ratajczak, 2011). The presence of MVs in body fluid make them easy accessible and analysis 
of their concentration and molecular composition can open a window on the damaged tissue	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(Camussi et al, 2010).   
As a consequence of cell activation elevated levels of MVs mainly derived from platelets, 
endothelial cells and tumor were reported in several pathologies such as cardiovascular disease, 
rheumatoid arthritis, sepsis, cancer and also in CNS diseases as summarized in table 1. Their levels 
may be a measure of inflammation, or predictive of metastasis in case of tumor derived MVs 
(ratajczak). Therefore extracellular MVs released from blood or tumor cells are emerging as new 
biomarkers from a specific tissue undergoing activation or damage (Doeuvre	  et	  al,	  2009). 
 
Table	  1:	  Cell-­‐derived	  microvesicles	  in	  CNS	  disease(Doeuvre	  et	  al,	  2009)	  
 
Clinical interest on MVs is not only related to their potential role as biomarkers of pathology. Also 
the possible therapeutic role of MVs has been recently considered.  
MVs derived from mesenchimal stem cells (MSC) have been reported to protect the kidney against 
ischemia–reperfusion-induced acute and chronic kidney injury. A single administration of MVs 
immediately after ischemia–reperfusion injury protected experimental animals from acute kidney 
injury by inhibiting apoptosis and stimulating tubular epithelial cell proliferation. This phenomenon 
was strongly dependent on mRNA present in MVs. Considering that MVs have specific targets and 
that do not interact with all cell types they can also be used as vehicle to delivery drugs or other 
molecules to specific cells in order to regulate the immune response such as in tumor or in organ 
transplantation (Camussi et al, 2010; Ratajczak, 2011). 
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1.2 Microglia in inflammation  	  
Microglial cells constitute 20% of the total glial cell population within the brain and are the resident 
macrophages of the central nervous system (CNS). These cells are derived from myeloid precursor 
that migrate into the CNS during embryogenesis	  (Kettenmann et al, 2011). 
After invading the brain parenchyma microglial cells precursors mature into a ramified cells 
characterized by a small soma and long thin process (Fig.4) and display the so-called “resting” 
or”surveillant” microglia phenotype. (Hanisch & Kettenmann, 2007) 
 
 
Although they are called resting, ramified microglial cells are far from inactive.  Studies based on in 
vivo two-photon microscopy on transgenic mice that express EGFP in the locus of CX3CR1 
chemokine receptor, demonstrates that the process of microglial cells are highly mobile and 
continuously survey their surrounding parenchyma without disturbing the fragile neuronal structure. 
It was estimate that the complete brain parenchyma could be monitored every few hours by 
surveillant microglia ss. The rapid scanning process rapidly changes to a targeted movement toward 
the site of injury when microlesion are induced. (Hanisch & Kettenmann, 2007)	  (Kettenmann et al, 
2011) 
One of the most remarkable properties of microglial cells is their ability to respond both to internal 
Fig.	  4:	  Resting	  microglial	  cell	   
	  	   16	  
signal such as damaged or stressed cells and to external signal like pathogens. Activation can be 
considered a stepwise transformation of resting cells that occurs upon disturbance of tissue 
homeostasis or upon experimental stimulation. 
Infection, trauma, ischemia, neurodegenerative disease, loss of brain homeostasis can evoke rapid 
and profound changes in the microglial cell shape, gene expression and functional behavior which 
summarily are defined as “activated” microglia	  (Hanisch & Kettenmann, 2007).  
During activation microglial cells change their appearance and acquire an amoeboid phenotype. 
Microglial cells also become motile, proliferate, unfold their phagocytotic activities, release 
chemoattractive factors and present antigen to T cells	  (Hanisch & Kettenmann, 2007).  
Regarding tissue resident macrophages, which represent the peripheral counterpart of microglial 
cells, several studies have shown that they can undergo two different forms of polarized activation. 
The first is the classic (M1) activation, characterized by high capacity to present antigen, high 
production of NO and ROS and of pro-inflammatory cytokines. M1 cells act as potent effectors that 
kill microorganisms and tumor cells, drive the inflammatory response and may mediate detrimental 
effects on neural cells. 
The second phenotype (M2) is an alternative apparently beneficial activation more related to a fine 
tuning of inflammation, scavenging of debris, promotion of angiogenesis, tissue remodeling and 
repair. Specific environmental signals are able to induce these different polarization states (Porta et 
al, 2009).A bipolar polarization has been also recently suggested for microglia, by showing that 
these cells, under certain conditions, can indeed be pushed to both extremes of the M1 and M2 
differentiation spectrum (Michelucci et al, 2009). Therefore, classically activated microglia (M1) 
refers to cytotoxic microglial cells which secrete ROS and proinflammatory cytokines. In contrast, 
alternatively activated microglia (M2) indicate myeloid brain cells that block proinflammatory 
responses and produce high levels of anti-inflammatory cytokines and neurotrophic factors	  
(Buechler et al, 2000). 
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1.3 Multiple sclerosis  	  
Multiple sclerosis (MS) is a leading cause of disability in young adults in the western world. 
(Compston & Coles, 2002).It is considered an autoimmune inflammatory demyelinating disease of 
the CNS.	  The disease is due to myelin autoreactive T cells, activated at the periphery, which cross 
the blood–brain barrier and drive an inflammatory process in the white matter. Clinically the most 
common form of the disease is partitioned into an early phase characterized by relapses an 
remission of neurological disability and a later chronic phase which shows a more progressive, non 
remitting feature (Compston & Coles, 2002). In	  MS	  patients,	  acute	  lesions	  in	  the	  nervous	  tissue	  are	   observed.	  These lesions are normally localized in the white matter and are characterized by 
breaking of the blood brain barrier, edema and demyelination, typical signals of an ongoing 
inflammatory process. In the last years, most of the research has focused on the inflammatory 
response of MS patients. The pathological hallmark of MS is, in fact, the presence within the CNS 
of inflammatory infiltrates containing few autoreactive T cells, a multitude of pathogenic 
nonspecific lymphocytes, macrophages and microglia	   (Prineas et al, 2001; Sriram & Rodriguez, 
1997). A significant microglia activation is present in all the major steps of MS, including the 
secondary progressive form. This is why it's believed that microglial activation underlies the 
insidious and persistent inflammation which mediate demyelination and progressive axonal loss in 
MS (Hemmer et al, 2002; Takahashi et al, 2003). The MS brain is also characterized by elevated 
levels of microglia-derived cytokines, including the pro-inflammatory cytokine IL1 beta, which is	  thought	   to	   have	   a	   major	   role	   in	   neuroinflammation.	   Microglia and peripheral macrophages, 
together with the products of inflammation (cytokines, nitroxide, etc.) and the variable participation 
of an antibody response, are currently considered the major sources of tissue lesion.  
A central point in understanding the pathogenesis of the MS is the role of inflammation and the 
relationship between inflammation, demyelination and axonal degeneration. There is still a 
consensus among most researchers that immunological process play a pivotal role in the 
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pathogenesis and progression of MS (Fig. 5) but there is also an alternative hypothesis that propose 
that activation of autoimmune cells is a consequence of toxic insults to CNS cells (Hauser & 
Oksenberg, 2006).  
 
1.4 Experimental autoimmune encephalomyelitis  	  
Experimental autoimmune encephalomyelitis (EAE) is the most widely used model of multiple 
sclerosis. Different types of EAE have been developed in order to investigate this heterogenic 
human disease (Mix et al, 2010).  
The history of EAE started in the first half of the 20th century; experiment were performed first in 
guinea pig and monkeys, and later in rat and mouse, enabling more extensive immuno-genetic, 
histopathological and therapeutic studies. 
Currently, the most common mode of EAE induction is based on the injection of an 
encephalitogenic peptide, mostly MOG 35-55 or PLP 139-151, which is emulsified in CFA containing 
Fig.	  5:	  Models	  of	  disease	  pathogenesis	  in	  MS.	  (Hauser	  &	  Oksenberg,	  2006) 
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mineral oil and Mycobacterium tuberculosis, followed by intraperitoneal injection of pertussis 
toxin(Mix et al, 2010). 
The phenotype of immunized animals depends mainly on the antigen source and the genetic 
background of the species and the strain of animal used. For example PLP induces relapsing 
remitting EAE in SJL mice, while MOG induces chronic-progressive EAE in C57BL mice	  (Gold et 
al, 2006; Mix et al, 2010). 
 
1.5 mir-146a in reactive microglia  	  
MicroRNAs represent an evolutionary conserved class of endogenous ~ 22 nucleotide non coding-
RNA that act as small regulatory molecules involved in post-transcriptional gene repression(Cao et 
al, 2006). Several miRNA have been described in the CNS and they are found to play a crucial role 
in several biological process. Among miRNAs present in the brain, Mir-146a is known to be an 
important regulator of the immune response. miRNA-146a is induced by different pro-
inflammatory stimuli, such as IL1-β and TNFα and its up-regulation is reported in various human 
pathologies associated with activation of inflammatory responses.	  (Aronica et al, 2010). Studies in 
recent years have shown that miRNAs have a unique expression profile in cells. For this reason they 
are emerging as potential biomarkers. Large miRNA expression studies have shown that miRNA 
profiles may reflect the differential status of a tumor and have supported the role of miRNA as 
either prognostic and/or diagnostic markers in various types of cancer (Calin & Croce, 2006; Rusca 
& Monticelli, 2011). 
In this context, a very interesting study by Ponomarev and colleagues recently demonstrated that 
expression of Mir-146a reflects the M1 pro-inflammatory phenotype displayed by microglia and 
peripheral macrophages during the active phase of EAE (Ponomarev et al, 2011). 
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2. Aim of the study 
 
Extracellular microvesicles (MVs) are important mediators of cell-to-cell communication and are 
emerging as new biomarkers of tissue damage.  
Results of the laboratory have recently shown that the typical danger signal ATP, which 
accumulates in the brain during inflammation, induces shedding of microvesicles (MVs) from 
microglia, which store and release pro-inflammatory cytokines. However no information is 
available about existence of microglia-derived MVs within the brain and of their possible biological 
activity. Although microglia are the immune cells of the CNS, which provide the first line of 
defense in brain pathologies (Graeber et al, 2011), all reports which exploited the diagnostic value 
of MVs in CNS diseases have focused so far on platelet-, endothelial cell- or oligodendrocyte-
derived MVs (Doeuvre et al, 2009; Emmanouilidou et al, 2010; Scolding et al, 1989). The 
possibility that microglia-derived MVs exist in vivo and may represent biomarkers of inflamed CNS 
has never been explored. 
Aim of the present study was to address this hypothesis  in the prototypic inflammatory disease of 
the CNS, multiple sclerosis (MS). 
Cerebrospinal fluid represents an easily accessible source of material for diagnosis and monitoring 
of neurological diseases. It is a potential indicator of abnormal CNS states such as inflammation, 
infection, neurodegenerative processes and tumor growth (Zougman et al, 2008). Therefore, to 
investigate the presence of microglia-derived MVs in vivo we analyzed by fluorescence 
microscopy, western blotting and flow cytometry the CSF collected from healthy rodents. We found 
that rodent CSF contains microvesicles (MVs) of microglial origin, similar in size and content to 
MVs released in vitro from microglia. We also showed that microglia-derived MVs deliver a pro-
inflammatory signal to glial cells, both to astrocytes and microglia, and that contribute to 
neuroinflammation in the course of Experimental Autoimmune Encephalomyelitis (EAE). All 
together these findings demonstrated a previously unappreciated role for microglia-derived MVs in 
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neuro-inflammation and identified microglial MVs as a novel biomarker of brain diseases 
characterized by microglia activation. 
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3.Material and methods 
 
3.1 Animals 	  
Sprague Dawley and Lewis rats, C57BL/6 and SJL/j mice were purchased from Charles River. A-
SMase KO mice (Horinouchi et al, 1995a) are a gift of Prof. Edward H. Schuchman. CX3CR1-
EGFP	  (Jung et al, 2000)  mice were provided by F. Kirchhoff.  
Animals were housed at constant temperature (22-18°C) and relative humidity (50%) under a 
regular light–dark schedule (lights on 7 a.m. to 7 p.m.). Food and water were freely available. All 
experiments were carried out in accordance with the European Communities Council Directive of 
24 November 1986 (86/609/EEC). All efforts were made to minimize animal suffering and to use 
only the number of animals necessary to produce reliable scientific data. 
 
3.2 Human patients 	  
Human CSF samples were obtained for diagnostic purpose from subjects with CIS (n=18) or 
definitive MS (n=40) according to revised McDonald’s criteria	  (Polman et al, 2011), attending the 
MS Center of the San Raffaele Hospital. Two patients had a primary progressive course (PPMS), 
while among relapsing remitting MS patients (RRMS), 23 were clinically stable and 15 were 
sampled during an acute attack. Two subjects with neuromyelitis optica (NMO), positive for NMO-
Ig, were also included in the analysis. CSF from age and sex matched healthy donors (n=7) without 
known neurological disease was collected from subjects undergoing local anesthesia for orthopedic 
surgery. This research project was approved by the ethical Committee of the San Raffaele Scientific 
Institute and all subjects signed a written informed consent.  
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3.3 Astrocytes and Microglia primary culture 	  
Primary mixed glial cultures from embryonic rat pups (embryonic days 20–21) were obtained as 
previously described (Bianco et al, 2009).  Dissociated cells were plated on poly-L-lysine-treated 
(10 µg/ml, Sigma-Aldrich) T75 flasks at density 1x106 cells/flask, and grown in MEM (Invitrogen 
Life Technologies) supplemented with 20% FCS (Gibco) and 100 IU/ml penicillin, 10 mg/ml 
streptomycin, and 5.5 g/L glucose (glial medium). Purified microglial cultures were harvested by 
shaking 2-weeks old mixed glial cultures.  1x106 microglia cells were plated onto poly-D,L-
ornithine-coated (final concentration 50 µg/ml; Sigma-Aldrich) 60mm tissue culture dish and 
maintained in the same medium.  
 
3.4 Hippocampal neuron 	  
Primary neuronal cultures were prepared from the hippocampi of 18-day-old fetal rats, as described 
by Bartlett and Banker (1984).  Dissociated cells were plated on poly-L-lysine-treated (1mg/ml, 
Sigma Chemical Co., St Louis, MO, USA) glass coverslips in Neurobasal medium (Invitrogen) 
supplemented with 2% B27 (Invitrogen).  
 
3.5 Isolation of MVs from cells 	  
MVs shedding is induced by treatment of microglial cells with ATP (1 mM) for 30 min in Krebs-
Ringer solution (125mM NaCl, 5mMKCl, 1.2mM MgSO4, 1.2mM KH2PO, 2mM CaCl2, 6mM D-
glucose, and 25mM HEPES/NaOH, pH 7.4). MVs were then isolated by differential centrifugation 
as previously described(bianco) The shedding vesicles were pelletted at 10.000 g for 30 min while 
exosomes were pelleted at 110.000 g., (Bianco et al, 2009). Micro BCA protein assay kit (Thermo 
Fischer Scientific) was used to determine the protein concentration, according to manufacturer’s 
specifications. We obtained 4,2± 0,15 µg of MVs (n=5, ±SE) from 1X106 primary microglia.  
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3.6 Isolation of MVs from rodent CSF 	  
Rats or mice have been anaesthetized by intraperitoneal injection of 4% Cloralium Hydrate; CSF 
has been sampled from the cisterna magna using a glass capillary and checked for the absence of 
blood contamination. CSF pooled from 2-5 rats has been diluted in ice-cold PBS containing 
protease inhibitors and subjected to differential centrifugation to obtain three vesicles pellets 
corresponding to larger shed vesicles (P2), smaller shed vesicles (P3) and exosomes (P4) (Bianco), 
or pelletted at 110,000g for 1h to obtain the whole MV fraction.  
  
3.7 Fluorescence microscopy  	  
MVs from rat or mouse CSF were re-suspended in 20 µl of PBS buffer and stained with Annexin-
V-FITC, CD11b-PE or IB4-FITC, spotted on glass slides and observed with an inverted Zeiss 
Axiovert 200M microscope. Staining of fixed MVs with Abs directed against intracellular epitopes, 
like Iba-1, GFAP, MBP and SNAP-25 was performed adding primary Ab was in a 1:1 volume of 
PBS buffer containing goat serum and 0.3% TritonX-100 and incubations were allowed for 1h at 
RT. Primary Ab-conjugated MVs were then washed with PBS and pelletted before incubation with 
fluorochrome-conjugated secondary Abs for 2h at RT and further washing in PBS. Re-pelletted 
labelled MVs were then spotted on glass slides and observed at the microscope. CSF collected from 
CX3CR1-EGFP mice was directly stained for Cd11b, spotted on glass microscope, sealed and 
analyzed. 
 
3.8 Mir-146a real time PCR 	  
MVs and exosomes were collected from 24x106 primary cortical astrocytes after exposure to ATP 
for 30 minutes. P2, P3 (shed vesicles) and P4 (exosomes) fractions were isolated by differential 
centrifugation as reported above. Total RNA was extracted from MVs pellet using MirVana 
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miRNA isolation Kit (ambion) following the manufacturer's protocol.  
TaqMan miRNA assays (Applied Biosystem) used the stem-loop method to detect the expression 
level of mature microRNA. As a first step total RNA was retrotrascribed using RT primer specific 
for the mir of interest; cDNA was then used for PCR reaction along with TaqMan primers. The RT 
primer, the TaqMan primer and probe for mir-146a and RNU6B, which was used for normalization, 
were from Applied Biosystem 
 
3.9 Mir-146a functional assay  	  
 To evaluate the levels intracellular mir-146a in neuronal culture a functional analysis was done 
using a luciferase-based assay. 
Primary culture of hippocampal neuron at DIV 6 were transiently transfected with 
PM146a/PsiCheck-2. In this the mature sequence of hsa-miR-146a in the antisense orientation was 
cloned downstream to the Renilla Luciferase coding region	  (Rom et al, 2010).  
The day after transfection cells were exposed to MVs released from microglial cells, approximately 
2,8 mg/ml. As positive control neuron were co-transfected with PM146a/PsiCheck-2 and 
mir146a/block-it a plasmid that induces the overexpression of mir-146a in the cells 	   (Rom et al, 
2010).  
 Twenty-four hours after the exposure to MVs, Firefly and Renilla luciferase activities were 
measured using the dual-luciferase assays (Promega) following the manufactures instruction. 
Briefly cells were washed in PBS and then scraped using the passive lysis buffer that is furnished 
with the kit. Renilla luciferase activity was normalized to firefly luciferase activity. 
 Plasmids were a gift from Peruzzi F. (LSU Health Sciences Center, New Orleans, ). 
 
3.10 Western blotting  	  
 MVs fraction collected from rat CSF as previously described were re-suspended in SDS sample 
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buffer, loaded on a single lane of a 12% polyacrylamide gel and blotted onto nitrocellulose filters. 
0,2µg of corpus callosum homogenate, 10 µg of rat brain and 1µg of cortical astrocyte lysate were 
run in the same gel, as positive controls. Selected proteins were detected with specific Abs followed 
by HRP-conjugated secondary Abs and revealed using an ECL system. Samples from MVs-
stimulated cultured astrocytes (10 µg) were processed similarly.  
 
3.11 Flow cytometry analysis of rodent and human CSF 	  
Human or mice CSF was directly stained with FITC-conjugate Isolectin B4 from Bandeiraea 
Simplicifolia, (IB4-FITC, SIGMA), and/or annexin-V-APC in 1% BSA. Specificity of IB4 labelling 
was evaluated on MVs produced by cultured microglia, by pre-treating IB4-FITC with 1M 
melibiose (6-O-a-D-galactopyranosyl-D-glucose) for 30 min as previously described (Ayoub & 
Salm, 2003). CSF was then diluted in PBS buffer and labelled MVs were acquired within a fixed 
time interval on a Canto II HTS flow cytometer (Becton Dickinson). Data were analyzed using FCS 
3 software (Becton Dickinson, Franklin Lakes, NJ, USA). Unstained and single-color controls were 
used to properly set PMT voltages and compensations. Forward scatter (FSc) height and width were 
used to discard doublets or aggregates. Using side-scatter (SSc) and FSc a vesicle gate was 
determined over the instrument noise (set by running PBS filtered through a 100 nm filter). Within 
this gate, IB4 positive events (number of events/µl) were evaluated as a parameter of myeloid MVs 
concentration in the CSF.  
In a first set of experiments, the vesicular nature of detected events was confirmed by using the 
lipophylic membrane styril-dye FM1-43. In addition, in vitro generated MVs were analyzed and 
sorted using similar FACS parameters on a FACSAria followed by fluorescence microscopy 
analysis. 
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3.12 Spectrophotometric quantification of shed MVs  	  
Spectrophotometric quantification of MVs shed from primary microglia was performed in Kreb’s 
Ringer.  Cells were incubated with 50µM NBD-C6-HPC (Molecular Probes, Invitrogen), washed 
and stimulated with 100µM BzATP for 20 min. Supernatant was collected, centrifuged 10 min 300g 
at 4°C to remove cells and debris, and the total fluorescence was assayed at 485/535 nm with the 
spectrophotometric system Tecan Infinite500, (TecanGroup Ltd , Switzerland). 
 
3.13 Glial cells cultures and in vitro stimulation 	  
Glial cells were exposed to either 0.4µg/ml LPS for 6 hours or Th1 cytokines (100 U/ml IL1-β, 200 
U/ml TNF  and 500 U/ml IFN ) for 48 hours. Recipient glial cells were exposed to an amount of 
MVs produced by twice as many donor microglia (1:2 receiving cells to donor cells relative ratio). 
At the end of activation, recipient glia were washed and either lysed in SDS sample buffer for 
western blotting or harvested with TRIZOL (invitrogen) for RT-PCR analysis or fixed with 4% 
paraformaldehyde for immunocytochemistry or loaded with the calcium dye FURA-2/AM 
(Invitrogen) for calcium imaging or analyzed by flow cytometry after surface staining with CD86-
PE for 20 min (at least 5 × 104 events/sample were analyzed).  
 
3.14 Semiquantitative reverse transcriptase-coupled PCR   	  
Total RNA was isolated from rat primary astrocytes/microglia  using miRNeasy Qiagen kit 
following the manufacturer’s protocol. To remove any contaminating genomic DNA, total RNA 
was digested with DNase. Reverse transcriptase was performed using SuperScript® III First-Strand 
Synthesis System (Invitrogen) and oligo (dT)20 as primer in a final volume of 20 µl. The resulting 
cDNA was amplified using FastStart Taq DNA Polymerase (Roche) and the following primers for 
rat proinflammatory genes IL-1β (339 bp), sense, 5’- CAG GAA GGC AGT GTC ACT CA -3’; 
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antisense, 5’- GGG ATT TTG TCG TTG CTT GT -3’; IL-6 (473 bp), sense, 5’- CCG GAG AGG 
AGA CTT CAC AG -3’; antisense, 5’-TGG TCC TTA GCC ACT CCT TC -3’; iNOS (595 bp), 
sense, 5’- AAG TCC AGC CGC ACC ACC CT -3’; antisense, 5’- TGC AGA CGC CAT GGT 
GCA GG -3’; CD206 (493 pb) sense, 5’- ACC TGG CAA GTA TCC ACA GC -3’; antisense, 5’-
TTT TCA GGC CTC AAT CCA AC -3’; COX-2 (334), sense,  5’-GAG CAC CTG CGG TTC 
GCT GT -3’; antisense, 5’-GCA GCA GCG GAT GCC AGT GA -3’;. Amplified products were 
electrophoresed on a 2% agarose gels and visualized by SYBR® safe staining. Actin (sense,  5’-
CTA GAA GCA TTG CGG TGG ACG ATG GAG GG -3’; antisense, 5’-TGA CGG GGT CAC 
CCA CAC TGT GCC CAT CTA -3’) was used to ascertain that an equivalent amount of cDNA 
was synthesized from different samples.  
Primer specific for the mouse and rat isoforms of IL-1β were also used: IL-1βrat (600 pb), sense 5’-
CCA AAT TCA ATT CAT CCC ATA-3’ antisense 5’-TGC CCG TGG AGC TTC CAG GA-3‘ 
and IL-1βmouse (500pb), sense 5’- GGG ATT TTG TCG TTG CTT GT-3’ antisense 5’- CCC TGG 
AGA TTG AGC TGT CTG-3’. All the primers were designed using Primer3 (REF). 
 
3.15 Quantitative real time PCR 	  
RNA was extracted from primari microglial cells and astrocytes as desribed above. cDNA synthesis 
from total RNA was performed using ThermoScriptTM RT-PCR system (Invitrogen) and Random 
Hexamers as primer. IL1-β, iNOS, COX-2, CD206, TGFβ and IL-10 mRNA levels were measured 
by real time PCR using Taqman® Gene Expression Assays on the ABI-Prism7000 sequence 
detection system (Applied Biosystems). 50 ng of starting RNA were used as template. The mRNA 
expression was normalized to the levels of GAPDH mRNA.  
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3.16 Cell fluorescence analysis of recipient glia 	  
Surface stainings for CD11b-PE and IB4-Texas red were carried out for 20 min at 4 °c or 3 min at 
RT, before fixing the cells. Iba-1, GFAP and phalloidin staining was performed on cells fixed with 
4% paraphormaldeyde. Nuclei were stained with 4′-6-diamidino-2-phenylindole (DAPI). Cells were 
mounted and observed with a Leica SP5 confocal microscope.  
 
3.17 [Ca2+]i determination 	  
Astrocytes, after exposure to shed MVs for 72h, were loaded with 10 µm Fura-2/AM for 45 min at 
37°C in culture medium. Polychrome IV (TILL Photonics) was used as a light source. Fura-2 
fluorescence images were collected after excitation at 340 and 380nm wavelengths and the emitted 
light was acquired at 505nm at 1–4 Hz. The ratio values in discrete areas of interest were calculated 
from sequences of images to obtain temporal analyses. Calcium concentrations were expressed as 
F340/380 fluorescence ratios. 
 
3.18 Lentivirus injections  	  
Mice were anesthetized with 2,2,2-tribromoethanol (10 mg/ml; 1/27 of body weight) and the head 
was placed in a stereotactic injection apparatus (David Kopf Instruments, Tujunga, CA, USA). 
Vesicular stomatitis virus-pseudotyped lentivirus (LV) LV-PGK-IFNγ and LV-PGK-TNFα, 
previously described in (Muzio et al, 2010), were injected within the right lateral ventricle at the 
following coordinates: A. +0; L. + 0.8 and D. −2.4. CSF was collected 10 days after lentivirus 
injection. 
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3.19 Relapsing-remitting and chronic rodent EAE  	  
Chronic progressive EAE (c-EAE) was induced in female C57Bl/6 mice by immunization with 
200µg/mouse of MOG35-55 (Espikem, Florence, Italy) and two injections of pertussis toxin 
(500ng/mouse) the day of immunization and 48 hours later. A reduced concentration of pertussis 
toxin (250ng/mouse) was used to induce EAE in 6 weeks old female A-SMase-/- mice and their 
littermates, in consideration of the young animal age, necessary to avoid interference with the 
inherent phenotype of these mice, consisting of ataxia and mild tremors which appears after about 
10 weeks of age	  (Otterbach & Stoffel, 1995). To obtain sub-clinical EAE for focal MV injections, 
mice were immunized with 50µg/mouse of MOG35-55 and 250ng/mouse of pertussis toxin. 
Relapsing-remitting EAE (r-EAE) was induced in female SJL/j mice by two immunizations, seven 
days apart, with 200 µg/mouse of PLP139-151 (Espikem, Florence, Italy) and four injections of 500ng 
of pertussis toxin the day of immunization and 48 hours later. CSF was collected at 10, 20, and 60 
days post injection (dpi), in c-EAE and at 29, 35, and 48 dpi, in r-EAE. Female Lewis rats weighing 
about 150gr were immunized under the skin of the flanks using 1mg lyophilized spinal cord 
homogenate emulsified in a total of 200µl of complete Freund adjuvant. Weight and clinical score 
were assigned according to a standard and validated 0 to 5 scale, described in g	  (Furlan et al, 2009) .  
 
3.20 MVs injections in EAE mice 	  
Mice with sub-clinical EAE, 20 days post immunization, were stereotactically injected in the corpus 
callosum (coordinates: 0 mm anterior, 1.0 mm lateral to the bregma and 2.2 mm in depth) with the 
whole fraction of vesicles (MVs and exosomes) derived from primary microglia dissolved in 1 µl of 
sterile saline (2µg/µl) or with liposomes, mimicking the phospholipid composition of the plasma 
membrane, which were prepared as follows: bovine brain PC, PS, SM and cholesterol (60:10:10:20, 
molar ratio), were dissolved in chloroform. The lipid mixtures were evaporated under a nitrogen 
stream, dried for 1 hour at 50°C and re-suspended in PBS at 40°C in order to obtain multilamellar 
	  	   31	  
vesicles. Small unilamellar vesicles were obtained by sonicating multilamellar vesicles. Mice were 
sacrificated  72 hours after MV/liposome injection to analyze formation of focal lesions at site of 
administration.  
 
3.21 Neuropathological analysis 	  
Brain tissue sections were fixed, embedded in paraffin and stained with H&E and Luxol fast Blue to 
reveal perivascular inflammatory infiltrates and demyelinated areas respectively. Infiltrating 
microglia and T cells were stained using IB4 and anti-CD3, revealed using a biotin-labeled 
secondary anti-rat antibody. Inflammatory infiltrates, demyelinated areas and axonal loss were 
quantified on an average of 10 complete cross-sections of spinal cord per animal. Perivascular 
inflammatory infiltrates, T cells, and macrophages were evaluated as the number per mm2, while 
demyelinated areas and axonal loss were expressed as the percentage per mm2. 
 
3.22 miRNA profiling 	  
To map miRNAs MVs and exosomes were isolated from 15x106 microglial cells exposed for 24 
hours to inflammatory Th1 cytokines and to the anti-inflammatory cytokines IL4. Total RNA has 
been isolated from MVs collected using miRNeasy mini Kit; cDNA has been prepared by a single 
in vitro transcription amplification step, using Universal cDNA synthesis kit (Exiqon) starting from 
22 ng of total RNA.  The obtained cDNA was used as template for microRNA quantitative real-
time PCR using microRNA Ready-to-Use PCR, Mouse&Rat panel I, V2.M (Exiqon). The 
experiment was run on  Roche LightCycler 480. Analysis of data has been carried out with GenEx 
software (Exiqon) using UniSp6 (Spike in RNA) as  calibrator and mir-499c as refefence gene. 
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3.23 Chemicals and antibodies 	  
ATP, BzATP, LPS, FICT- and APC-annexin V, IB4-FITC, IB4-Texas red, phalloidin-Texas red, 
melibiose were from Sigma-Aldrich. CellTracker green CMFDA, were from Molecular Probes, PI 
was BD Biosciences, NBD-C6-HPC was from Invitrogen, IL1-β was from Euroclone, TNFα and 
IFNγ from Peprotech. The following antibodies were used: anti mouse CD11b-PE (BD 
Biosciences), anti human CD63-PE (BD Biosciences) anti-rat CD86 (eBioscience), anti-mouse 
GFAP (Sigma-Aldrich), anti-human calnexin (Sigma-Aldrich), anti-mouse CNPase (Chemicon), 
anti-mouse MBP (Chemical), anti-mouse SNAP-25 SMI 81 (Sternberger Monoclonals) anti-mouse 
Iba-1 (Wako), anti-CD3 (Serotec Ltd), anti-OX42 (Harlan Sera-Lab, UK). PC, PS, cholesterol and 
SM were from Sigma-Aldrich. 
 
3.24 Statistical Analysis  	  
All data are presented as mean or median + SD or SE from the indicated number of experiments. 
Data were compared using the Student's t-test for parametric data or the Mann–Whitney U-test for 
non-parametric data or non normally distributed data. Differences were considered to be significant 
if p<0.05 and are indicated by an asterisk; those at p<0.01 are indicated by double asterisks, and 
p<0.0001 by triple asterisk. 	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4. Results 
 
4.1 MVs shedding is increased upon inflammation  	  
The release of shedding vesicles takes place in resting cells, but it is increased upon stimulation 
such as during inflammation and in tumor cells. 
To verify whether the activation state of microglia may influence MV production, cultured 
microglia were exposed for 48 hours to Th1 cytokines (IL-1β- TNF - IFN ). Cells were incubated 
in vivo with antibodies directed against CD11b, then were fixed with PFA 4% and counter stained 
for Iba1. Fluorescence microscopy analysis showed the presence of several blebs at the cell surface, 
characterized by Iba1 accumulation in Th1 treated cells not detectable in unstimulated cells. (Fig. 6) 
This finding suggests that exposure to a pro-inflammatory enviroment may strongly induce the 
process of shedding in microglial cells.   
  
 Consistent	  with	  the	  ability	  to	  induce	  massive	  formation	  of	  blebs	  at	  the	  cell	  surface,	  spectrometric	  quantification. of ATP-induced MVs shedding from resting microglia and cells pre-
Fig. 6: MVs shedding in activated cells. Primary microglia exposed to Th1 cytokines for 24h, showing numerous 
blebs at the plasma membrane enriched in Iba-1 (upper panels). Double staining for surface CD11b and Iba-1 in 
control and Th1-treated BV2 microglial cells (lower panels).The histogram shows the spectrophotometric 
quantification of MVs shed from resting or reactive microglial cells, prelabelled with NBD-C6-HPC and exposed to 
the P2X7 agonist BzATP (100 µM) for 20 min 
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activated with Th1 cytokines or LPS indicated that Th1 cytokines are the best priming stimuli for 
the process(Fig.6) 
 
4.2 MVs interaction with glial cells: astrocytes and microglia 	  
To evaluate whether microglia-derived MVs may have a pathological role in inflammation we 
analyzed the effect of MVs on primary glial cells both astrocytes and microglia. 
1x106 astrocytes were exposed for 48 hours to MVs released from 2x106 microglial cells (ratio 1:2) 
at concentration of 2 µg/ml. After exposure to MVs astrocytes appeared e more reactive, they 
looked hypertrophic, displaying more thicker process, and showed higher levels of GFAP (Fig. 7). 
72 hours after exposure to MVs we also evaluate basal calcium concentration of astrocytes exposed 
to MVs. produced either from LPS or TH1 primed microglial cells. To this aim, cells were loaded 
with the fluorescent calcium dye FURA-2, and calcium levels were analyzed evaluating F340/F380 
fluorescence ratio. We found that that astrocytes exposed to MVs have higher basal calcium 
concentration as compeared to control cells, confirming that they are activated.  
To further analyze the phenotype acquired by astrocytes after exposure to MVs we used semi-
quantitative PCR and Real Time PCR. 
Exposure of astrocytes to MVs produced by LPS-treated microglia induced up regulation of the 
Fig. 7: Effect of MVs on astrocytes.  1-Fuorescent staining for the activation marker GFAP of naïve cortical astrocytes 
and astrocytes exposed to MVs shed from LPS-treated microglia. 2-Western blotting for GFAP of control astrocytes and 
astrocytes activated by MVs ; the endoplasmic reticulum protein calnexin was used as loading control. 3-Cytoplasmic 
calcium concentration, expressed as F340/380 fluorescence ratio, of astrocytes, loaded with the fluorescent calcium dye 
FURA-2, 72 hours after exposure to MVs produced from LPS- or Th1-treated microglia. 	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pro-inflammatory markers iNOS, COX-2, IL1β, IL6 and COX-2 as indicated by both by semi-
quantitative PCR and real time PCR without changing the level of expression of the anti-
inflammatory molecules TGF-β and IL-10. Inflammatory markers were induced in a dose-
dependent manner, as indicated by linear correlation between the amount of MVs, used as a 
stimulus, and level of expression of markers of astrogliosis in recipient astrocytes.	  Of	  note,	  a	   less	  robust	  response	  was	  evoked	  by	  MVs	  produced	  by	  resting	  microglia	  (Fig.8).	   
 
 
Similar results were obtained on microglial cells exposed to MVs. 
Microglia cells responded to MVs by up-regulating the T-cell co-receptor ligand CD86 at the cell 
surface, mimicking the effects induced by exposure to the inflammatory stimulus LPS. This was 
indicated by flow cytometry analysis of surface expression of CD86 in control microglia and cells 
exposed to MVs (Fig. 9). Microglia-derived MVs were also able to stimulate expression of 
inflammatory markers (iNOS, COX-2, IL6, IL1beta) and to reduce the level of expression of the 
Fig. 8: MVs shed from microglia deliver a pro-inflammatory signal to astrocytes.  1-2 RT-PCR for COX-2, IL-6, IL-
1β, and iNOS mRNA in control cells, astrocytes activated overnight with LPS or exposed for 48 hours to MVs 
produced by resting or LPS--treated microglia. Both amplicons run on agarose and real time quantitative evaluation 
are shown. 3- dose-response correlation between concentration of MVs and induction of inflammatory markers 
	  	   36	  
M2 marker CD206, the mannose-6 phosphate receptor, as indicated by quantitative real time and 
semi-quantitative PCR analysis (Fig. 9). A treatment of 48 hours with MVs was necessary to induce 
these variations in the expression of  mRNAs. 
Activation of glial cells was likely mediated by interaction of MVs with recipient cells and 
subsequent MV internalization into their cytoplasm. This was indicated by confocal analysis of N9 
microglial cells exposed for 1h to GFP labeled MVs ,released from N9 cells, stably expressing 
GFP. As shown in Fig. 10, staining with the f-actin ligand phalloidin clearly revealed the presence 
of GFP-labelled MVs inside the cytoplasm of a recipient N9 cell.  
To further study the interaction of MVs with target gial cells we also did a surface staining for IB4-
Texas red (red) in primary microglia exposed to MVs derived from CMFDA-loaded microglia 
(green). CMFDA-storing MVs were incubated with recipient microglia for 1h and microglia were 
briefly exposed to IB4-PE and gently washed before being fixed. This protocol allows staining with 
Fig. 9:	  MVs shed from microglia deliver a pro-inflammatory signal to microglial cells 1- Fluorescent images revealing 
increased surface expression of the activation marker CD86 (red) in primary microglia exposed overnight to LPS, as 
compared to control. Nuclei are shown in blue with DAPI staining.  2- Quantitative flow cytometry analysis of CD86 
surface expression in microglia maintained in control condition, treated for 3 hours with LPS or incubated overnight 
with MVs derived from Th1-primed microglial cells.3- RT-PCR for inflammatory genes and for the proregenerative 
marker CD206 in control microglia and cells stimulated with Th1 cytokines or LPS, or exposed to MVs derived from 
either resting or LPS/Th1-primed donor microglia. Amplicons run on agarose gels, compared to actin, and real time 
quantitative analysis. 
 
	  	   37	  
IB4 of only MVs attached to the cell surface of receiving microglia but not of those already 
internalized into the cells. As shown in Fig. 10, some CMFDA-loaded MVs were IB4 negative 
(arrows), indicating that they were already internalized into the cytoplasm 
To evaluate whether MV internalization into recipient cells may be associated to transfer of 
cytoplasmic components I settled up a PCR based assay based on the use of primers specific for 
murine IL1β mRNA.  
	   	  
Fig. 10: MVs interact with by recipient glial cells. 1- Confocal images of N9 cells exposed for 1 h to GFP-labelled 
MVs, isolated from the medium of GFP-expressing N9 cells, fixed and stained with the f-actin ligand phalloidin. 
2- Surface staining for IB4-Texas red (red) of primary microglia exposed to CMFDA-labelled MVs (green), 
derived from CMFDA-loaded microglia. CMFDA-storing MVs were incubated with recipient microglia for 1h 
and microglia were then briefly exposed to IB4 and gently washed before being fixed. 3- PCR amplification of 
mouse IL-1b mRNA in rat microglia exposed to MVs derived from mouse microglia. 4- Expression of 
inflammatory marker induced from MVs, MVs depletet of the content, Annexin V coated MVs and to lipid 
fraction extracted from MVS revealed by Real Time PCR 
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1x106 rat primary microglia cells were incubated for 5 hours with MVs released from mouse 
microglial cells. Cells were then extensively washed before extraction of RNA and amplification 
with mouse specific primers.   Because the low amount of mouse mRNA a nested PCR was 
necessary. Amplicons were then run on agarose gel. As shown in figure 10 mRNA for the mouse 
isoform of IL1 beta was present in rat microglia cells incubated with mouse MVs, thus indicating 
that MVs transfer cytoplasmic components to recipient microglia. We next evaluated whether 
interaction of MVs with the surface of target cells and MV internalization may contribute to the 
pro-inflammatory response of receiving cells. To this aim astocytes were exposed to artificially 
broken MVs, depleted of their content, to the lipid fraction of MVs or to MVs in which externalized 
PS, that is determinant for recognition on recipient cells, was masked by annexin V. Our 
preliminary data suggested that inhibition of MV interaction by annexin-V stongly reduce  the 
capability of MVs to activate an inflammatory response. Furthermore these data suggested that  that 
the active components of MVs are located in the MVs lumen rather than in the MV surface. 
However, further experiments are necessary to confirm that propagation of the inflammatory signal 
is mediated  by MV cargo and to identify the components responsible for the inflammatory activity 
of MVs	   
 
4.3 Mir-146a in MVs 	  
Since mir146a is expressed in primary human fetal microglia and a large amount of small RNAs, 
including microRNA (miRNA) has been described in extracellular vesicles (Valadi et al, 2007) we 
evaluate the possibility that mir146a was present in microvesicles. 
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To assess the presence of mir146a, RNA was extracted from MVs and exosomes produced from the 
N9 microglia cell line, either unstimulated or exposed or to LPS, and analysed by Real Time PCR. 
Graph in figure 11 shows that mir146a is present in both shed vesicles (P2-P3 population) and 
exosomes (P4) and that its expression is increased in vesicles released	  from LPS primed cells. 
	  
4.4 MVs interaction with neuron	  	  
Recent data of the laboratory have shown that microglia-derived MVs can also interact with the 
surface of recipients neurons, maintained in primary culture. Confocal analysis of hippocampal 
neurons exposed for 1 hour to GFP-labelled MVs, extensively washed and processed for 
immunocytochemistry, revealed the presence of MVs anchored to the surface of neuronal processes 
as showed in figure 12.	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Fig. 11: mir-146a in glial MVs. LPS induced upregulation of  mir-146a is in glial MVs and exosomes 
revealed by Real Time PCR 
Fig. 12: MVs shed from microglia interact with neuronal surface. MVs shed from N9 microglial cells, 
stably expressing GFP were incubated for 1 h whit hippocampal neurons. Culture were then fixed and 
stained for the plasma membrane protein SNAP-25. 
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I therefore evaluated the possibility that MVs could transfer luminal components to neuronal 
cytoplasm. By the used of the assay described above I cannot observe any IL1β mRNA transfer 
from glial MVs to neuron. To confirm this result by a different methodology approach I 
investigated the possible transfer of mir146a from microglia-derived MVs to neurons. The levels of 
expression of mir-146a were evaluated using a functional assay based on luciferase activity. Neuron 
were transfected with a reporter construct that contain the Renilla Luciferase gene fused to the 
perfect match sequence of mir-146a; the plasmid also contained the firefly luciferase gene for 
normalization. Transfected neurons were then incubated in presence of glial MVs for 24 hours and 
the mir-146a levels were evaluated by dual luciferase assay. As shown in figure 12 the exposure of 
neuron to MVs or exosomes induced a significant down-regulation of Renilla luciferase activity 
indicating an increase in the levels of mir-146a in the cells as compare to control cells. As positive 
control we evaluated the reduction of Renilla luciferase activity in neuron transfected with mir-
146a; in this sample we observe a reduction of around 70% of luciferase activity.	  	  
	  
These data indicate that the levels of mir-146a are increased in neurons exposed to MVs and 
exsosomes. Data obtained clearly indicated an increase of mir146a in neurons exposed to MVs. 
However it is not clear at the moment whether this increase results from upregulation of the mirna 
or transfer.. 
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Fig. 13: Dual luciferase assay on mir-146a activity.	  Levels	  of	  mir146a	   in	  cells	  exposed	  to	  MVs	  and	  exosomes	  were	   analyzed	  using	  a	   luciferase	   reporter	   sensitive	   to	  mir-­‐146a.	   As	  positive	   control	  mir146a	   expression	  was	  induced	  in	  cells.	  The	  reduction	  in	  luciferase	  activity	  indicate	  an	  increase	  in	  the	  levels	  of	  mir146a. 
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4.5 MVs in rodent CSF 	  
To demonstrate the existence in vivo of microglia-derived MVs the cerebrospinal fluid collected 
from healthy rodents was recently analyzed in the laboratory by negative staining electron 
microscopy. Analysis of three distinct pellets (P2,P3 and P4) obtained by differential centrifugation 
of rat CSF showed that extracellular vesicles, similar in size to both MVs and exosomes, released in 
vitro from glial cells, are indeed present in the cerebrospinal fluid of healthy rats. (Fig. 13) 
 
To better characterize these vesicles, rodent CSF was also analyzed by fluorescence microscopy 
(Fig. 15). The membrane vesicles pelleted from the CSF (P2-P4 fraction) were stained with the 
fluorescent phosphocholine analog NBD-C6-HPC to label the lipid bilayer of the vesicles.  
 
 
 
Fig. 14: MVs in rodent CSF. MVs of decreasing size isolated from the CSF of healthy rats by differential 
centrifugation (P2, P3, P4 fractions) and analyzed by negative staining EM. Corresponding frequency histograms, 
indicating the size distribution of MVs pelleted at increased centrifugal force, are shown on the right. 
	  	   42	  
 
 
They were also stained with specific markers for shed vesicles or exosomes, such as Annexin V, 
that binds to phosphatidyl serine on the outer leaflet of the MVs plasma membrane and CD63 that is 
a typical exosomal marker. This analysis confirmed the exosome nature of part of CSF vesicles and 
the plasmamembrane origin of larger vesicles.	   
Rodent CSF was also analyzed by fluorescence microscopy or western blot analysis in order to 
evaluate the cellular origin of MVs. Vesicle fractions were isolated by differential centrifugation the 
pellets stained with fluorescent markers for distinct cell types and observed at confocal microscope. 
Alternatively vesicle fractions were solubilized for WB analysis with the same markers. We 
observed vesicles immunopositive for markers of distinct brain populations, i.e. SNAP-25 for 
neurons, GFAP for astrocytes and MBP and CNPase oligodendrocytes. These data indicated that 
MVs can be released from all these cell types (Fig. 16). To assess the presence of microglial MVs 
in the CSF we analyzed the CSF of CX3CR1-EGFP transgenic mice, in which microglial cells 
express the green fluorescent protein GFP.  The presence of  EGFP+ MVs in the CSF of these mice 
is a clear demonstration of the microglial origin of some CSF MVs. that are positive also for the 
microglial marker CD11b stained in red.  
 
Fig. 15: MVs in the CSF of healthy rodents. Examples of CSF MVs analyzed by fluorescence microscopy using 
the fluorescent phosphocholine analog NBD-C6-HPC to label the lipid bilayer of MVs,  the shed MVs marker 
annexin-V-FITC, and the exosomal marker CD63 
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The existence of microglia derived microvesicles was also confirmed with fluorescent microscopy 
and immunogold electro-microscopy staining MVS with specific microglial markers such as Iba1, 
IB4-FITC and OX-42(CD11b). 
 
4.6 Quantification of MVs in the CSF 
Cerebrospinal fluid represents an easily accessible source of material for diagnosis and monitoring 
of neurological diseases. It is a potential indicator of abnormal CNS states such as inflammation, 
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Fig. 16: Origins of MVs in the CSF of healthy rodents. Confocal microscopy and WB analysis of the CSF 
collected from healthy rodents revealed MVs displaying neuronal (SNAP-25), astrocytic (GFAP), 
oligodendroglial (MBP-CNPase) and microglia (Iba1, IB4 CD11b) markers. Fluorescence micrographs of EGFP+ 
MVs present in the CFS of CXCR3-EGFP transgenic mice, stained for the microglia marker CD11b-PE before 
microscope observation. 
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infection, neurodegenerative processes and tumor growth (Zougman et al, 2008). CSF is the only 
body fluid in direct contact with the brain and therefore can act as a recipient of shedding products 
release by neuronal cells. With the objective of quantify MVs in the CSF of rodent we settled up a 
cytofluorimetric assay specific for microglia derived MVs.  
 
 
Flow cytometry analysis is a quantitative and reliable methodology to measure MVs, and it has 
been already used to detect small extracellular vesicles, exosomes, in samples of human plasma. A 
gate was established on size, using beads of 0.5-2 µm, to analyze particles ranges from 50 to 1000 
nm. Within this gate, IB4 events were evaluated as parameter of MVs concentration. CSF sample 
were directed immunolabeled with IB4-FITC in order to avoid the formation of immuno complexes 
that can be detectable within the MVs gate. To asses the specificity of IB4 labelling we use 
Fig. 17: IB4 labeling of microglia-derived MVs. Differential interference contrast microscopy (right panels) and in 
vivo fluorescent labeling for IB4-FITC (left panels) of rat microglia in primary cultures. Note that IB4-FITC 
pretreatment with 1M melibiose, a specific ligand for the isolectin IB4, completely prevents its binding to the surface 
of microglial cells, confirming specificity of the staining. Melibiose pretreatment completely abolished IB4-FITC 
labeling, confirming the specificity of the FACS assay. 
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melibiose, a specific ligand for the isolectin IB4. Pretreatment with 1M melibiose completely 
prevents IB4 binding to the surface of microglial cells confirming the specificity of the staining. 
(Fig. 17) FACS analysis of   microglia MVs pretreated with melibiose completely abolished IB4-
FITC staining, confirming the specificity of the FACS assay (Fig. 17).  
 
4.7 CSF MVs during neuroinflammation 	  We	   and	   others	   have	   shown	   that	   both	   the	   typical	   danger	   signal	   ATP	   and	   bacterial	  lipopolysaccharide	   greatly	   enhance	   the	   release	   of	  MVs	   and	  MV-­‐dependent	   secretion	  of	   IL1-­‐beta	   and	   MHC-­‐II,	   in	   vitro,	   from	   microglia	   (Fig.	   6	   Bianco	   et	   al.,	   2005;	   Qu	   et	   al.,	   2009).	   To	  evaluate	   if	  a	  similar	  phenomenon	  occurs	   in	  vivo,	  healthy	  C57BL/6	  mice	  were	  stereotaxically	  injected	  into	  the	  ventricular	  cavity	  with	  lentiviral	  vectors	  codifying	  for	  the	  pro-­‐inflammatory	  cytokines	  INF-­‐γ	  or	  TNFα.	  This protocol is known to induce a strong infiltration of macrophage and 
the expansion of microglia in the periventricular area and in the choroid plexus (Muzio et al, 2010). 
Consistently the confocal analysis of the choroid plexus isolated from mice, ten days after the 
injection and labeled with microglial marker Iba1 and DAPI, showed a significant increase in 
microglial cells Iba1 positive in TNF  and IFN  injected mice. (Fig. 18) Analysis by flow 
cytometry of MVs of myeloid origin indicated that intrathecal release of pro-inflammatory cytokine 
dramatically increased microglia-derived MVs of myeloid origin in the CSF. Giving the proof of 
principle that microglia-MVs were increased in vivo in inflammatory conditions.  
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4.8 CSF MVs in EAE 	  
We then analyzed rodents affected by experimental autoimmune encephalomyelitis (EAE), a 
neuroinflammatory model for human multiple sclerosis (MS). Quantitative analysis of MVs in mice 
affected by chronic or relapsing EAE, mimicking the two most common clinical forms of MS, 
showed that the amount of total MVs, and myeloid MVs was closely associated to disease course, 
increasing at onset and during clinical relapses, and decreasing in the chronic phase of the disease 
(Fig 19). During EAE, myeloid cells enter the CNS from the blood stream and accumulate in both 
parenchimal and meningeal perivascular inflammatory infiltrates. Choroid plexi, which have been 
identified as the site of first entry of inflammatory cells during EAE (Kivisakk et al, 2009)  
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Fig. 18: The amount of microglia-derived MVs in the CSF increases upon inflammation  1-Representative choroid 
plexus from mice injected with lentiviral vectors encoding for GFP (control), TNFα or IFNγ, ten days after injection. 
Staining for Iba-1(red) and DAPI, to label nuclei (light blue) 2- Flow cytometry analysis of IB4+ MVs in the CSF 
collected from naïve mice, sham mice and mice injected with the lentiviral vectors. 
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are in close contact with the CSF and present therefore the more plausible source of myeloid CSF 
MVs. 
 
In the last panel was reported a representative FACS analysis of MVs in the CSF of EAE mouse 
compare to a control. Those data open the possibility that MVs can be an useful biomarker to 
monitor the disease progression. 
 
4.9 Can MVs propagate an inflammatory signal in vivo? 	  
To evaluate whether microglia-MVs can have a role in the propagation of an inflammatory signal in 
vivo during EAE stereotactically injected MVs derived from cultured microglia into the brain of 
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Fig.19: The amount of microglia-derived MVs in the reflects EAE activity. 1-Histogram shows the percentage of 
IB4+ MVs in the CSF of naïve mice, mice injected with lentivirus codifying for TNFα, and mice affected by chronic 
(c-) or relapsing-remitting (r-) EAE. 2- Flow cytometry analysis of IB4+ CSF MVs at different disease stages during 
relapsing remitting (r-EAE) and chronic (c-EAE) 3- Representative flow cytometry scatter plots of IB4+ and 
annexin-V+ CSF MVs collected from a naïve mouse and a EAE mouse, in the chronic phase of the disease.  
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mice affected by subclinical EAE. Injections were performed into the corpus callosum, a site 
usually devoid of inflammation during EAE. Seventytwo hours after injection we found 
perivascular inflammatory foci close to the site of injection in all MVs-injected EAE mice and in 
none of saline- or liposome-injected controls (Fig. 12). Inflammatory perivascular infiltrates were 
constituted by very few CD4+ T cells and a vast majority of IB4+ microglia. These data suggest 
that MVs may contribute to formation of focal inflammatory lesion. 
 
4.10 Pathogenic role of MVs 	  
We have previously shown the enzyme acid sphingomyelinase (A-SMase) controls the budding of 
MVs from the plasma membrane and that MV shedding is abolished in A-SMase KO glial cells. 
Therefore, to further explore the pathogenic role of MVs in vivo we induced EAE in A-SMase KO 
mice. Since these mutants develop neurological signs starting from 10-12 weeks of age, EAE was 
induced in 6 weeks-old animals and the disease was monitored until 8 weeks of age. Notably, 
ASMase KO mice were highly resistant to the development of EAE as compared to wild type 
Fig. 20: Microglia-derived MVs amplify brain inflammation. Coronal sections of the brain of EAE mice injected 
in the corpus callosum with MVs or liposomes mimicking the phospholipid composition of the plasma membrane. 
Triple staining for DAPI (blue), Iba1 (red) and CD4 (green) shows perivascular inflammatory infiltrates in mice 
injected with MVs  but not with control. 
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littermates (Fig. 21). The lower score of A-SMase KO mice was associated with an expected lower 
amount of myeloid MVs in the CSF, reduced perivascular infiltrates and absence of tissue damage 
in the spinal cord, confirming that shed MVs may have pathogenic functions during EAE. 
 
 
 
4.11 Human sample 	  
In order to verify whether the increase in microglia derived MVs that we demonstrate in the CSF of  
EAE mice can be extended to humans, we collected CSF from healthy donors, patients with 
Clinically Isolated Syndrome (CIS), patients with definite primary progressive or relapsing-
remitting multiple sclerosis (PPMS and RRMS, respectively), the latter during a stable phase of the 
disease (stable RRMS), or during an acute attack (acute RRMS). Quantitative flow cytometry 
analysis of IB4 positive microvesicles was done. Similar to data obtained in the animal model IB4 
positive MVs were significantly increased in the CSF from CIS and relapsing RRMS patients (Fig 
22), when inflammatory processes are at higher levels. 
These data indicate that CSF MVs represent novel in vivo biomarker of microglia/macrophage 
Fig. 21: Pathogenic role of microglia-derived MVs. 1-2-3Body weight and median and cumulative clinical score of A-
SMase KO mice and WT littermates affected by c-EAE 4- FACS analysis of IB4+ MVS in CSF of EAE-A-SMase 
KOmice and EAE WT littermate 5-6 Quantification of IB4+macrophages and CD3+ T cells in the spinal cord of EAE 
A-SMase KO mice and WT littermates.  
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activation. 
 
 
4.12 MVs miRNA profiling 	  
To address the possibility that CSF MVs contain miRNA signatures that specifically reflect 
microglial activation occurring in the brain during neuroinflammatory disease we carried out a 
profiling of miRNAs present in extracellular vesicles.  
We analyzed by Real Time PCR the expression of 376 microRNAs in MVs and exosomes released 
from control cells as well as from cells exposed to Th1 pro-inflammatory cytokines (IL1-b, TNFa, 
INFg) and to IL4, an anti inflammatory cytokine. We observed a differential expression of several 
miRNAs (~110) in our samples. As shown in figure 23 some miRNAs were expressed only in TH1 
extracellular vesicle; other were expressed only in IL4 vesicles or in control cells. We also 
compared the expression data on microRNA present in vesicles with those present in parental cells. 
Interestingly we detected in vesicles miRNA that are not present in cells, indicating that some 
miRNAs may be uniquely packed into MVs and/or exosomes (Fig. 24). Nevertheless, these data are 
very preliminary and the presence of the microRNA identified as significantly up-/down-regulated 
in MVs need to be confirmed by quantitative real-time PCR. 
Fig. 22: Microglia derived MVs in Multiple sclerosis patients. Quantitative flow cytometry analysis of IB4+ 
positive MVs in human CSF collected from CIS patients, relapsing remitting MS patients in a clinical and 
neuroradiological stable (stable RRMS) or acute (relapsing MS) phase of the disease, primary progressive MS 
patients, patients with neuromyelitis optica and age-and sexmatchedcontrols . 
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Fig. 23: miRNAs relative expression in extracellular vesicles. Heatmap of the relative expression of miRNA 
in MVs and exosomes release from differently activated microglial cells. The wap was done at 
http://www.chibi.ubc.ca/matrix2png/bin/matrix2png.cgi 
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Fig. 24: Relative abundance of miRNAs in MVs released from Th1 primed microglia compared 
to parental cells . 
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5 Discussion 	  
5.1 Inflammatory role of Mvs in vitro 	  
Microglial cells constitute the resident macrophage population in the brain. They are generally 
considered the immune cells of the CNS. They show a resting phenotype in normal CNS where they 
provide tissue maintenance and immune surveillance	  (Cameron & Landreth, 2010). Microglia cells 
become promptly activated in response to alteration of brain homeostasis	  (Hanisch & Kettenmann, 
2007).  
We and others have shown that both the typical danger signal ATP and the bacterial membrane 
component lipopolysaccharide (LPS) enhance the release of MVs (Bianco et al, 2009a; Qu et al, 
2007) Here we show that Th1 cytokines (TNF-α, INF-γ and IL1-β)  are the best priming stimuli to 
mediate shedding of MVs and that microvescicles shedding takes place very efficiently in microglia 
exposed in vitro to a pro-inflammatory environment. Several study indicate that microvesicles 
contribute to inflammation via their influence on cell-cell communication and cytokine release. In 
this work we demonstrate that microglia derived microvesicles are able to propagate an 
inflammatory signal to glial cells. iNOS, IL1beta, IL6, COX2 expression is increased in astrocytes 
and microglia exposed to MVs as indicated from Real Time PCR analysis. Interestingly MVs 
produced by microglia exposed to an inflammatory environment, such as those released from LPS 
primed microglia, induced a stronger up-regulation of the inflammatory markers in recipient glial 
cells.  
Microvesicles may influence the behaviour of target cells in several ways, including the transfer of 
protein, mRNAs and miRNAs (Ratajczak et al, 2006). Our data indicate that MVs can be 
internalized from microglial cells and astrocytes in culture and as a consequence of this process, 
mRNAs that are present inside the MVs are transferred to recipient cells. Nevertheless the role of 
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MVs internalization and mRNA transfer in the propagation of the inflammatory signal remain to be 
largely explored.   
We also show that MVs can interact with the surface of cultured neurons, thereby causing an 
increase in the levels of mir-146a in hippocampal cultures. Mir-146a is an inflammatory 
microRNA, and its expression is induced by NF-kB activation (Aronica et al, 2010). Hence, the 
increase in Mir-146a suggest that MVs propagate an inflammatory signal to neurons, besides glial 
cells. However, lack of detectable levels of murine mRNA for Il1 beta in the extract from rat 
neurons exposed mouse MVs, indicate that MVs fail to transfer components from their lumen to the 
neuronal cytoplasm. Based of this observation, it is unlikely that the increase in mir-146 levels 
evoked in neurons by MV exposure is mediated by a direct transfer of the miRNA.  Although 
further study are required to clarify this point, it is likely that MVs induce an up-regulation of 
neuronal of mir-146a through the activation of inflammatory pathway in neurons. 
 
5.2 Role in vivo of microglia-derived MVs 	  
Previous studies indicated that microglia and other myeloid cells in vitro can shed MVs, which 
store and release the pro-inflammatory cytokine IL-1b, together inflammosome components  	  
(Mathivanan et al, 2010) and MHCII protein, a central player in the adaptive immune response 	  (Qu 
et al, 2007). These data suggest that MVs produced from reactive myeloid cells may propagate 
inflammation and provide an efficient route for rapid dissemination and presentation of antigens. 
This possibility has been clearly demonstrated by the in vitro experiments described in this thesis. 
In addition, recent results of our laboratory indicated that microglia-derived MVs interact with the 
plasma membrane of neurons and enhance excitatory transmission (Antonucci  et al., in press), 
possibly contributing to the excessive potentiation of neurotransmission, which occurs in 
neuroinflammatory diseases (Centonze et al, 2009a). However, whether MVs of microglial origin 
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exist and play a role in vivo was still elusive. Aim of this work was to investigate the existence of 
MVs of microglia origin in vivo and to explore their possible role during inflammatory brain 
diseases. We showed, by electron and fluorescence microscopy, the presence of MVs positive for 
myeloid markers in the CSF of healthy rodents and humans, indicating that myeloid cells can 
secrete MVs in vivo. Given peripheral macrophages are virtually absent in healthy brain 
parenchyma, the presence in the CSF of MVs positive for myeloid markers or derived from 
CX3CR1-EGFP expressing cells suggest that MVs originate from resident microglia in the normal 
brain. However, MVs may also originate from the low number of macrophages which are present at 
choroid plexus and within leptomeninges in the uninjured brain. The capability of MVs to travel 
away from parechymal microglia and to enter the CSF is consistent with the presence in the CSF of 
MVs of neuroectodermal origin, including neurons and oligodendrocytes, that are strictly 
parenchymal and have no contact with liquoral space. Neurons and astrocytes have been described 
to release MVs in vitro(Faure et al, 2006),(Taylor et al, 2007),(Bianco et al, 2009b). However, to 
our knowledge, this is the first evidence that rodent and human CSF contain MVs derived from 
these brain cells.  
Quantification of MVs by flow cytometry indicated an increase in the absolute amount of 
microglia/macrophages MVs in EAE mice. Choroid plexus, which is in direct contact with the CSF 
and has been identified as the site of first entry of inflammatory cells and peripheral macrophages 
during EAE(Engelhardt et al, 2001; Kivisakk et al, 2009), represent the more plausible source of 
increased amounts of myeloid MVs during neuroinflammation. Consistent with this possibility 
myeloid MVs were detected in plexus from from mice injected with inflammatory cytokines. Due 
to the fact that small volumes of CSF collected from single mice do not allow the use of beads for 
exosome capture(Gyorgy et al, 2011),(Ostrowski et al, 2010), exosomes cannot be accurately 
analyzed by flow cytometry. We could not therefore distinguish between the two populations of 
extracellular membrane vesicles of myeloid origin. However, the majority of events above the 
detection limit of  the flow cytometer most likely represents large MVs, originating from the plasma 
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membrane of microglia/macrophages. Consistent with this possibility, MVs of larger size were 
detected by EM in the CSF of EAE rats as compared to naive animals.  
One of the main accomplishments of this study is the finding that the concentration of 
microglia/macrophage-derived MVs in mouse CSF reflects the course and severity of EAE. 
Consistently, the amount of MVs in human CSF is higher in patients presenting with the first 
clinical symptom of MS or in relapsing patients as compared to patients in a stable phase of the 
disease or healthy controls. These results link the events of microglia activation and infiltration of 
peripheral macrophages to the process of MV secretion. They also identify CSF myeloid MVs as 
novel biomarkers of microglia/macrophage activation in vivo, useful as companion tool for disease 
diagnosis and for monitoring the efficacy of drugs targeting MS. Microglia is considered at the 
crossroad between inflammation and neurodegeneration with both detrimental and protective 
roles(Ransohoff & Cardona, 2010; Schwartz & Shechter, 2010). The evidence that different 
methods of activation result in different functional phenotypes of myeloid cells, ranging from 
purely phagocytic and tissue destructive, to immuno-modulating and promoting tissue 
remodeling(Biswas & Mantovani, 2010), has led to the idea that suppressing microglia or 
modulating/redirecting its activation holds a therapeutic potential for progressive forms of MS and 
for neurodegenerative disorders(Centonze et al, 2009b). However, information on the quality of the 
microglial activation in vivo in humans is missing as are reliable biomarkers to monitor the efficacy 
of drugs targeting activated microglial cells. We propose that MVs produced by 
microglia/macrophages and leaking into the CSF may represent a rich source of information on 
microglia/macrophage activation in the brain, which may lead to the identification of specific 
disease cell signature through the analysis of their content.  
The second main accomplishment of our study is the demonstration that increased amounts of 
microglia/macrophage-derived MVs actually promote neuro-inflammation The pro-inflammatory 
activity of MVs was demonstrated in vitro by the dose-dependent induction of inflammatory 
markers in recipient glial cells. The glial reaction was associated to MV interaction and transfer of 
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IL-1β mRNA in the cell cytoplasm. Accordingly, our unpublished observation suggested that MVs 
depleted from their luminal content greatly lose their capacity to activate target astrocytes and the 
lipid fraction from MVs only weakly stimulates the expression of inflammatory markers in 
astrocytes, thus ruling out that phospholipids of microglia-derived MV are responsible for the 
inflammatory activity. However, further studies are required to identify the active component of 
MVs and to determine whether MV internalization and transfer of genetic information contribute to 
the pro-inflammatory response target cells. The pathogenic role of MVs in the inflammatory 
response was demonstrated in vivo by showing that injection of microglia-derived MVs induces the 
formation of inflammatory foci at the site of delivery. This was further corroborated by the finding 
that A-SMase KO mice, genetically impaired in MV production, are largely protected from EAE. 
Mice lacking A-SMase develop a phenotype similar to Niemann-Pick type A disorder(Horinouchi 
et al, 1995b),(Otterbach & Stoffel, 1995), an inherited disease characterized by progressive visceral 
organ abnormalities and neurodegeneration, that leads to growth retardation and death in early 
childhood. A-SMase KO mice appear normal at birth and develop normally until about 8-10 weeks 
of age, when ataxia and mild tremors become noticeable, as a result of Purkinje cell 
neurodegeneration (Otterbach & Stoffel, 1995). Of note, despite growth defects, incipient 
neurodegeneration and the slight gliosis in the gray and white matter (Otterbach & Stoffel, 1995) 
we found that 8 week-old EAE KO animals were about 20% more the weight of EAE WT 
littermates. Moreover, EAE KO mice displayed no demyelinating lesions and less perivascular 
infiltrates in the spinal cords as compared WT littermates, thus strongly linking A-SMase 
deficiency and impairment in MV shedding to EAE amelioration.  
 Give these data MVs are a unique way for exchanging integrated signals, targeting MVs may 
represent a therapeutic strategy more advantageous than classical approaches aimed at neutralizing 
single inflammatory molecules in MS.  
From the data exposed in this thesis Microglia derived MVs are emerging as new biomarkers for 
neuroinflammatory desease. To address the possibility that CSF MVs contain signatures which 
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specifically reflect microglial activation occurring in neuroinflammatory disease  we analyse their 
miRNAs contents. RNAs profiling of human MVs is hardly feasible, due to the small amount of 
organelles available for the analysis. Therefore we will identify putative multiple sclerosis markers 
by mapping miRNAs expressed in MVs shed in vitro upon activation with either Th1 inflammatory 
cytokines and anti-inflammatory cytokine (IL4).  
Data collected from the miRNAs Exiqon’s panels revealed several miRNAs that are differently 
expressed in MVs. Moreover miRNA that are significantly up-/down-regulated in MVs shed from 
Th1 microglia as compared to resting cells or cells stimulated with IL4, will be confirmed by 
quantitative real-time PCR and their expression will be evaluated by Real Time PCR also in MVs 
isolated from the CSF of MS patients or healthy donor 
 
5.3 Conclusions 	  
Overall our data link activation of myeloid cells in vivo to propagation of MVs, as cargo structures 
delivering pro-inflammatory signals, and identify myeloid MVs as a novel therapeutic target and a 
companion tool for MS diagnosis. 
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